Pancreatitis in the trial data
Each document reports a different slice of the evidence. The US label uses its broadest pool: nine placebo- and active-controlled trials in which 4,116 people took the tablets for an average of 59.8 weeks [1]. Europe adds adjudicated cases, confirmed by an independent committee, from the phase 3a trials and from two cardiovascular trials, PIONEER 6 (the US label’s Trial 8) and SOUL (Trial 7) [1][2]. Canada repeats the SOUL figure [3].
| Source and trials | Semaglutide tablets | Comparison |
|---|---|---|
| US PI 6.1, nine controlled trials: serious pancreatitis [1] | 6 people (0.1 per 100 patient-years) | 1 person (under 0.1) |
| EU SmPC 4.8, phase 3a: confirmed acute pancreatitis [2] | under 0.1% | 0.2% (comparators) |
| EU SmPC 4.8, PIONEER 6 (Trial 8) [2] | 0.1% | 0.2% (placebo) |
| EU SmPC 4.8 and Canadian PM 7, SOUL (Trial 7) [2][3] | 0.4% | 0.4% (placebo) |
| EU frequency class [2] | “Rare” (up to 1 in 1,000) | — |
Why a rare event still carries a warning
In the controlled trials the numbers are small and, in the outcome trials, level with placebo [1][2][3]. A large 2025 meta-analysis of 55 placebo-controlled trials with 106,395 participants reached a similar conclusion for GLP-1 medicines as a group: probably little or no effect on pancreatitis risk [4]. Trials, however, may exclude people at higher risk and are too small to rule out rare harms.
Outside trials, pancreatitis stands out. Among 2,398 US FDA reports for semaglutide tablets, it was one of the most reported problems with a strong signal, with 117 reports [5]. Reports cannot give a rate or prove cause, but they explain why the label keeps the warning, and its section 6.2 lists acute and necrotising pancreatitis, sometimes fatal, among reports after approval [1][5].
Enzymes, gallstones and other possible links
- From the label: in the placebo-controlled trials, average amylase rose by 10% to 13% and lipase by 30% to 34% on the tablets, but not on placebo [1]. The label presents these as laboratory findings and does not tie them to pancreatitis in individuals.
- A plausible chain, not measured for Rybelsus®: NIH names gallstones as the most common cause of acute pancreatitis [6], and gallbladder disease is itself a Rybelsus® warning [1]. No study cited here shows how many pancreatitis cases on the tablet began with a gallstone.
- Not attributed: none of the documents links pancreatitis to the tablet’s absorption enhancer, SNAC [1][2][3].
What pancreatitis pain is like
NIH describes acute pancreatitis as upper abdominal pain that starts slowly or suddenly, may spread to the back, can be mild or severe and may last for days, often with fever, nausea, vomiting, a fast heartbeat and a swollen, tender belly; people usually look and feel seriously ill [6]. MedlinePlus adds that the pain may get worse soon after eating, especially fatty food, may be worse lying flat and may reach below the left shoulder blade [7].
The Rybelsus® Medication Guide keeps it short: intense belly pain that persists, whether or not you feel sick or vomit, at times reaching the back [1]. The EU leaflet describes pain in the stomach and back that does not go away and asks you to see a doctor immediately [2].
Other causes, and lowering the odds
NIH lists gallstones, heavy alcohol use, genetic conditions and some medicines as the most common causes, and infections, abdominal injury, a pancreatic tumour and certain endoscopic procedures as others [6]. MedlinePlus adds very high triglycerides and medicines such as oestrogens, corticosteroids, thiazide diuretics, sulfonamides and azathioprine [7]. In many cases no cause is found [6].
To lower the risk of a first or repeat episode, MedlinePlus suggests not drinking alcohol if it was the likely cause, not smoking and treating conditions that raise triglycerides [7]. The Rybelsus® Medication Guide asks you to tell your provider before starting if you have or have had pancreas problems [1].
After a suspected episode
The US label tells prescribers to stop the tablets if pancreatitis is suspected and start appropriate management, and asks patients to stop and call promptly [1]. Europe and Canada go a step further: if pancreatitis is confirmed, semaglutide should not be restarted [2][3]. Because semaglutide stays in the body for about five weeks after the last tablet, your clinician will plan around that [1].
Do not take the next morning’s tablet before you have spoken to your provider, and tell them when the pain began, whether it reaches your back and whether you have vomited.
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that does not go away, with or without vomiting, sometimes through to the back | Stop Rybelsus® and call your provider right away | Emergency | Rybelsus® Medication Guide [1] |
| Severe or worsening belly pain with fever or chills, a fast heartbeat or shortness of breath | Seek care right away; emergency services if very unwell | Emergency | NIDDK [6] |
| Belly pain with yellow skin or eyes | Seek care right away | Emergency | NIDDK [6] |
| Intense, constant abdominal pain | Your provider | Today | MedlinePlus [7] |
| A past episode of pancreatitis, before starting or restarting Rybelsus® | Your prescriber | At your next appointment | Rybelsus® Medication Guide [1]; EU SmPC [2] |
